Articles liés à Current and Emerging First-line Therapies in Renal...
Current and Emerging First-line Therapies in Renal Clear-cell Cancer: Rapidly evolving landscape in renal cell cancer - Couverture souple
Synopsis
Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Acheter neuf
Afficher cet article
EUR 26,90
EUR 23 expédition depuis Allemagne vers Etats-Unis
Destinations, frais et délaisRésultats de recherche pour Current and Emerging First-line Therapies in Renal...
Image fournie par le vendeur
Current and Emerging First-line Therapies in Renal Clear-cell Cancer
Edité par
LAP LAMBERT Academic Publishing Nov 2019, 2019
ISBN 10 : 6200463115
ISBN 13 : 9786200463111
Neuf
Taschenbuch
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era. 52 pp. Englisch. N° de réf. du vendeur 9786200463111
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
Current and Emerging First-line Therapies in Renal Clear-cell Cancer
Edité par
LAP LAMBERT Academic Publishing, 2019
ISBN 10 : 6200463115
ISBN 13 : 9786200463111
Neuf
Kartoniert / Broschiert
Vendeur : moluna, Greven, Allemagne
Évaluation du vendeur 4 sur 5 étoiles
Kartoniert / Broschiert. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Tegos TheodorosDr Theodoros Tegos holds a PhD degree on First-line therapies in metastatic clear-renal cell carcinoma . Currently he is working in the Oncological Department of the Evangelismos General Hospital in Athens, Greece. Hi. N° de réf. du vendeur 335816642
Quantité disponible : Plus de 20 disponibles
Image fournie par le vendeur
Current and Emerging First-line Therapies in Renal Clear-cell Cancer
Edité par
LAP LAMBERT Academic Publishing Nov 2019, 2019
ISBN 10 : 6200463115
ISBN 13 : 9786200463111
Neuf
Taschenbuch
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. Neuware -Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.Books on Demand GmbH, Überseering 33, 22297 Hamburg 52 pp. Englisch. N° de réf. du vendeur 9786200463111
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
Current and Emerging First-line Therapies in Renal Clear-cell Cancer : Rapidly evolving landscape in renal cell cancer
Edité par
LAP LAMBERT Academic Publishing, 2019
ISBN 10 : 6200463115
ISBN 13 : 9786200463111
Neuf
Taschenbuch
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era. N° de réf. du vendeur 9786200463111
Quantité disponible : 1 disponible(s)